Abstract

VILAZODONE: A UNIQUE SPARI WITH STELLAR HYBRID ACTION

*Dr. Ranjan Bhattacharyya, Dr. Mainak Ghosh, Dr. Sumita Bhattacharyya, Dr. Jayanta Pal, Dr. Nephaur Rahaman and Dr. Rajarshi Bhadra

ABSTRACT

Introduction: Vilazodone is a SERT inhibitor and partial agonist of 5HT1A receptor introduced as a new antidepressant. The dual mechanism of action attributes to faster onset of antidepressant action and more rapid improvement of symptoms. Methodology: The systemic review of available literatures including pubmed, google scholar, science direct, cochrane database has been reviewed with the available search engines. Results: The molecular structure, pharmacodynamics, pharmacokoinetics, mechanism of action, adverse reactions has been described. The outcome measures has been compared in between disease related and patient related evidences. The commonest adverse effects are nausea, diarrhoea and headache which decrease with time. Because of less drug interaction, suitable for geriatric patients with comorbidities. Conclusion: The therapeutic evidences have been summarized in a chart. The therapeutic efficacy is established and the molecule is generally well accepted and can be ffective first line antidepressant, even in severely depressed patients.

Keywords: vilazodone, SERT & SPARI, antidepressant, review.